Conor Announces Positive EuroSTAR Six-Month Follow-Up Data

Conor Medsystems has announced six-month follow-up data that demonstrate favorable clinical results for the treatment of single or multiple de novo lesions in native coronary arteries.

EuroSTAR (EUROpean cobalt chromium STent with Antiproliferative for Restenosis) is a prospective, multicenter, pivotal study evaluating the safety and performance of Conor Medsystem's CoStar stent for the treatment of restenosis. A total of 176 lesions were treated in 145 patients using the CoStar stent formulated to release a therapeutic dose of 10 mcg of paclitaxel over approximately 30 days - based on in vitro measurements.

At six-month follow-up, the target lesion revascularization rate was 1.7 percent, and the rate of cumulative major adverse cardiac events was 4.8 percent. Complete six-month angiographic results and clinical data from the first arm of the EuroSTAR study will be presented at the Cardiovascular Research Foundation-sponsored symposium immediately preceding the American College of Cardiology meeting in Orlando, Fla., in March. The CoStar stent is not available for sale in the U.S. and is undergoing clinical investigation in the European Union.